Hepatitis Forums
Advanced Liver Disease Main Forums => Advanced Liver Disease => Topic started by: Hep Editors on December 05, 2018, 11:32:18 am
-
The Food and Drug Administration (FDA) this week approved the checkpoint inhibitor Keytruda (pembrolizumab) for people with hepatocellular carcinoma (HCC), the most common type of cancer that originates in the liver.
The accelerated approval is supported by data from the Phase II KEYNOTE-224 trial, which showed that Keytruda reduced the risk of disease progression or death compared with standard treatment in people who previously used targeted therapy.
Read more...
https://www.hepmag.com/article/fda-keytruda-pembrolizumab-livercancer